Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levosimendan for Acute Ischemic Stroke (ChiCTR2500110769)
ChiCTR2500110769Phase 4Recruiting
- Sponsor
- The First Hospital of Jilin University
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of levosimendan in ischemic stroke (2 arms), sponsored by The First Hospital of Jilin University. Primary endpoint: Proportion of mRS 0–1 at 90±7 days. Started Oct 2025; status: recruiting.
02
Drugs
levosimendan
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR2500110769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110769.